Onco-Nefrología: cáncer, quimioterapia y riñón

Galceran, 2017, Cancer incidence in Spain, 2015, Clin Transl Oncol., 19, 799, 10.1007/s12094-016-1607-9 Otero, 2010, Prevalence of chronic renal disease in Spain: Results of the EPIRCE study, Nefrologia., 30, 78 Ronco, 1999, Paraneoplastic glomerulopathies: New insights into an old entity, Kidney Int., 56, 355, 10.1046/j.1523-1755.1999.00548.x Glezerman I, Jaimes EA: Chemotherapy and kidney injury. American Society of Nephrology Onco-Nephrology Curriculum. Disponible en: https://www.asn-online.org/education/distancelearning/curricula/onco/Chapter11.pdf. Edeani A, Cohen EP. Radiation nephropathy. American Society of Nephrology Onco-Nephrology Curriculum. Disponible en: https://www.asnonline.org/education/distancelearning/curricula/onco/Chapter10.pdf Huang, 2006, Chronic kidney disease after nephrectomy in patients with renal cortical tumours: A retrospective cohort study, Lancet Oncol., 7, 735, 10.1016/S1470-2045(06)70803-8 Maisonneuve, 1999, Cancer in patients on dialysis for end-stage renal disease: An international collaborative study, Lancet., 354, 93, 10.1016/S0140-6736(99)06154-1 Kasiske, 2004, Cancer after kidney transplantation in the United States, Am J Transplant., 4, 905, 10.1111/j.1600-6143.2004.00450.x Monga D, Jhaveri KD. Glomerular diseases and cáncer. American Society of Nephrology Onco-Nephrology Curriculum. Disponible en: https://www.asn-online.org/education/distancelearning/curricula/onco/Chapter6.pdf De Francisco, 2018, Daño renal agudo asociado a la administración intravascular de contraste yodado en el paciente de riesgo y oncológico. Una posición de expertos, Nefrología Kougias, 2014, Impact of cumulative intravascular contrast exposure on renal function in patients with occlusive and aneurysmal vascular disease, J Vasc Surg., 59, 1644, 10.1016/j.jvs.2013.12.039 Hong, 2016, Contrast-induced nephropathy in patients with active cancer undergoing contrast-enhanced computed tomography, Support Care Cancer, 24, 1011, 10.1007/s00520-015-2875-6 2012, KDIGO Clinical Practice Guideline for acute kidney injury, Kidney Inter Suppl, 2, 1 Sharma, 2014, Renal functional reserve and renal recovery after acute kidney injury, Nephron Clin Pract., 127, 94, 10.1159/000363721 Janus, 2010, Cancer and renal insufficiency results of the BIRMA study, Br J Cancer., 7, 1815, 10.1038/sj.bjc.6605979 Canter, 2011, Prevalence of baseline chronic kidney disease in patients presenting with solid renal tumors, Urology., 77, 781, 10.1016/j.urology.2010.11.050 Nakamura, 2011, Prevalence of anemia and chronic kidney disease in cancer patients: Clinical significance for 1-year mortalit, Nihon Jinzo Gakkai Shi., 53, 38 Königsbrügge, 2014, Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality, Thromb Res., 134, 44, 10.1016/j.thromres.2014.04.002 de Francisco, 2010, Under-recognized renal insufficiency in hospitalized patients: Implications for care, Eur J Intern Med., 21, 327, 10.1016/j.ejim.2010.04.011 Wong, 2016, Chronic kidney disease and the risk of cancer: An individual patient data meta-analysis of 32,057 participants from 6prospective studies, BMC Cancer, 16, 488, 10.1186/s12885-016-2532-6 Stengel, 2010, Chronic kidney disease and cancer: A troubling connection, J Nephrol., 23, 253 Arias, 2018, Cáncer en el trasplantado renal: ¿se puede prevenir?, Nefrología, 9 Cancer report. En: Clayton P, McDonald S, Hurst K, editores. Australia and New Zealand Dialysis and Transplant Registry. 2013 Annual report. 36th ed. Adelaide: ANZDATA; 2014. Kim, 2012, Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: A systematic review and meta-analysis, J Urol., 188, 51, 10.1016/j.juro.2012.03.006 Li, 2014, Risk of chronic kidney disease after cancer nephrectomy, Nat Rev Nephrol, 10, 135, 10.1038/nrneph.2013.273 Campbell, 2009, Guideline for management of the clinical T1 renal mass, J Urol., 182, 1271, 10.1016/j.juro.2009.07.004 Ljungberg, 2015, EAU guidelines on renal cell carcinoma: 2014 update, Eur Urol., 67, 913, 10.1016/j.eururo.2015.01.005 Miyamoto, 2009, Potential for molecularly targeted therapy against epidermal growth factor receptor ligands, Anticancer Res., 29, 823 Sharma, 2011, VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: Present and future, Curr Cancer Drug Targets., 11, 624, 10.2174/156800911795655985 Laplante, 2012, mTOR signaling in growth control and disease, Cell, 149, 274, 10.1016/j.cell.2012.03.017 Buchbinder, 2016, CTLA-4 and PD-1 pathways, Am J Clin Oncol, 39, 98, 10.1097/COC.0000000000000239 Wood, 2017, The biology and therapeutic approach to BRAF-Mutant cutaneous melanoma, AJHO., 13, 4 Davar, 2012, Role of PARP inhibitors in cancer biology and therapy, Curr Med Chem., 19, 3907, 10.2174/092986712802002464 Hamilton, 2016, Targeting CDK4/6 in patients with cancer, Cancer Treatment Reviews, 45, 129, 10.1016/j.ctrv.2016.03.002 Jhaveri, 2018, Chimeric antigen receptor T cell therapy and the kidney: What the nephrologist needs to know, Clin J Am Soc Nephrol., 13, 796, 10.2215/CJN.12871117 Scott, 2012, Antibody therapy of cancer, Nature Reviews Cancer, 12, 278, 10.1038/nrc3236 Hasan, 2018, Antibody-drug conjugates: A review on the epitome of targeted anti-cancer therapy, Curr Clin Pharmacol., 13, 236, 10.2174/1574884712666180802095521 Selamet, 2017, Chronic kidney disease as complication of cancer, Onco-Nephrol, 1, 74, 10.5301/jo-n.5000010 Pezarella, 2018, Nephrotoxicity of cancer immunotherapies: Past, present and future, J Am Soc Nephrol, 29, 2039, 10.1681/ASN.2018050488 Cosmai L, Porta C, Perazella MA, Launay-Vacher V, Rosner MH, Jhaveri KD, et al. Opening an onconephrology clinic: Recommendations and basic requirements. Nephrol Dial Transplant. 2018;33(9):1503-1510. Xipell, 2018, Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy, Oncoimmunology., 26, e1445952, 10.1080/2162402X.2018.1445952